Trasutuzumab versus observation for high-risk,...

Trasutuzumab versus observation for high-risk, non-metastatic, HER2 non-amplified breast cancer with Circulating Tumor Cells (EORTC 90091-10093 Treat CTC): A European, multicenter, randomized phase 2 trial

Ignatiadis, M., Litiere, S., Rothe, F., Riethdorf, S., Proudhon, C., Fehm, T., Aalders, K., Forstbauer, H., Fasching, P., Brain, E., Vuylsteke, P., Guardiola, E., Lorenz, R., Pantel, K., Tryfonidis, K
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
92
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(18)30263-6
Date:
April, 2018
File:
PDF, 47 KB
english, 2018
Conversion to is in progress
Conversion to is failed